Merz, Maximilian
Hielscher, Thomas http://orcid.org/0000-0003-1277-310X
Mai, Elias Karl http://orcid.org/0000-0002-6226-1252
Seckinger, Anja
Hose, Dirk
Jauch, Anna
Sauer, Sandra
Luntz, Steffen
Bertsch, Uta
Raab, Marc S.
Neben, Kai
Salwender, Hans
Blau, Igor W.
Lindemann, Hans-Walter
Dürig, Jan
Scheid, Christof
Haenel, Mathias
Weisel, Katja
Weber, Tim
Delorme, Stefan
Goldschmidt, Hartmut
Hillengass, Jens
Article History
Received: 7 June 2019
Revised: 1 July 2019
Accepted: 5 August 2019
First Online: 27 August 2019
Conflict of interest
: The GMMG MM5 Trial (EudraCT no. 2010–019173–16) is supported by grants from Janssen-Cilag, Celgene, Chugai and The Binding Site. H.G.: Celgene: Consultancy, Honoraria, Research Funding; Chugai: Research Funding; Janssen Cilag: Consultancy, Honoraria, Research Funding. J.D.: Janssen Cilag: Honoraria; Celgene: Honoraria. E.K.M.: Janssen: honoraria, travel grant; Takeda: honoraria, travel grant, advisory board; Celgene: travel grant; Onyx: travel grant; Munidpharma: travel grant. H.-W.L. Honoraria: Amgen, Novartis, Takeda und Celgene M.M. AMGEN: advisory board and travel grants. Takeda: advisory board, travel grants and research support; Celgene: travel grant Schmidt-Wolf: Janssen Cilag: Honoraria; Novartis: Honoraria. K.W.: Janssen Cilag: Consultancy, Honoraria; Celgene: Consultancy, Honoraria, Research Funding. C.S.: Janssen Cilag: Honoraria; Celgene: Honoraria; Novartis: Honoraria. H.S.: Janssen Cilag: Honoraria; Celgene: Honoraria. All other authors declare that they have no conflict of interest.